Enhancing Biologics with CESI-MS Characterization

May 18, 2020 | Biopharma, Blogs | 0 comments

Comprehensive characterization of a biologic requires analysis at both the intact and digest levels, but these analyses can be complex and cumbersome. For example, with conventional liquid chromatography separations, researchers are often left with limited information due to problems with either very small or very large protein and peptide retention. Unfortunately, slow going methods like these do not mesh with the rapid onset of novel drug approvals and researchers are left wanting more.  As in, a more reliable and comprehensive process for characterizing biologics to move them through the drug development pipeline, without compromising on results.Download the Latest Biologics Research >

Go with the CESI-MS Flow
The good news is there are alternatives to existing workflows. For example, using CESI coupled with mass spectrometers (CESI-MS), researchers gain a more comprehensive biologic outlook while at the same time saving almost a day’s worth of time in the lab. Intrigued? We’ve put together in an online eBook that provides vivid illustrations, application notes, and video demonstrations for a solid multi-level characterization biologic foundation, and it’s all here for the taking. This is not your typical brochure, but rather a self-guided tour to be shared with your co-workers as they ask questions and get immediate answers to their most pressing characterization questions. Discover ways to advance your biologics characterization studies using instrumentation like the CESI 8000 Plus coupled with a TripleTOF® mass spectrometer. Together, they give you high-resolution separations with the unique detection capabilities and dedicated software designed for biologics analysis.  From intact analysis to peptide mapping, get an inside look at how CESI-MS can advance your investigations of glycosylation, a drug to antibody ratio (DAR), disulfide bond mapping, and PTM identification. Go inside the lab and see the instrument at work using single injection technology for multi-level characterization of a biotherapeutic. Alternatively, view a video showing how powerful software solutions can help you to simplify your comparability work– all in this feature-rich online guide. It’s an interactive tour that gives you all the insight you need for linking CESI technology to high-performance mass spec.

 

PFAS testing: 2024 in review and what to expect for 2025

For as long as PFAS persist in the environment, there is no doubt they will persist in our conversations as environmental scientists. Globally, PFAS contamination has been detected in water supplies, soil and even in the blood of people and wildlife. Different countries are at various stages of addressing PFAS contamination and many governments have set regulatory limits and are working on assessing the extent of contamination, cleaning up affected sites and researching safer alternatives.

Inside the box: Acoustic ejection mass spectrometry for drug discovery

On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.

Unveiling the power of ZT Scan DIA: Insights from Ludwig Sinn’s presentation at World HUPO Congress 2024

In a recent presentation at the World HUPO Congress 2024, Ludwig Sinn from the Ralser lab shared exciting advancements in proteomics research, focusing on the innovative ZT Scan DIA acquisition modes developed in collaboration with SCIEX. Let us explore the key highlights and benefits of this innovative technology.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial